PATENT CLAIM ANALYSIS

Application Number: 15999336
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-04
Patent Classification: ["514", "001400"]

Abstract:
Use of a αVβ3 antagonist such as cilengitide or a functional variant thereof for the treatment or prevention of sepsis in a patient is described, in which the cilengitide is delivered to the patient intravenously.

Claim (Index 2):
A method according to  claim 1  in which the functional \u03b1V\u03b23 antagonist is a low molecular weight antagonist.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 96.0
- Lexical Diversity: 1.37037
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13386323', '10298461', '12128545', '12611090', '11412754']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.756687497313632
- 35 USC 102 Novelty (BERT): 0.4981085157330106
- Combined Prediction Score: 0.73082959915557
- Mean Citation Score: 200.026956
- Max Citation Score: 208.50128
- Similarity Product: 138.6929625777054

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test